Primary Granulocyte Colony-Stimulating Factor Prophylaxis During the First Two Cycles Only or Throughout All Chemotherapy Cycles in Patients With Breast Cancer at Risk for Febrile Neutropenia | Zendy

Maureen J.B. Aarts | Zendy; Frank Peters | Zendy; Caroline Mandigers | Zendy; M. Wouter Dercksen | Zendy; Jacqueline M. Stouthard | Zendy; Hans J. W. R. Nortier | Zendy; Hanneke W.M. van Laarhoven | Zendy; Laurence J. van Warmerdam | Zendy; Agnès J. van de Wouw | Zendy; Esther Jacobs | Zendy; Vera Mattijssen | Zendy; Carin C.D. van der Rijt | Zendy; Tineke J. Smilde | Zendy; Annette W. van der Velden | Zendy; Mehmet Temizkan | Zendy; Erdogan Batman | Zendy; E.W. Muller | Zendy; Saskia M. van Gastel | Zendy; George F. Borm | Zendy; Vivianne C. G. TjanHeijnen | Zendy

Open Access

Primary Granulocyte Colony-Stimulating Factor Prophylaxis During the First Two Cycles Only or Throughout All Chemotherapy Cycles in Patients With Breast Cancer at Risk for Febrile Neutropenia

Author(s) -

Maureen J.B. Aarts,

Frank Peters,

Caroline Mandigers,

M. Wouter Dercksen,

Jacqueline M. Stouthard,

Hans J. W. R. Nortier,

Hanneke W.M. van Laarhoven,

Laurence J. van Warmerdam,

Agnès J. van de Wouw,

Esther Jacobs,

Vera Mattijssen,

Carin C.D. van der Rijt,

Tineke J. Smilde,

Annette W. van der Velden,

Mehmet Temizkan,

Erdogan Batman,

E.W. Muller,

Saskia M. van Gastel,

George F. Borm,

Vivianne C. G. TjanHeijnen

Publication year - 2013

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2012.44.6229

Subject(s) - medicine , febrile neutropenia , chemotherapy , granulocyte colony stimulating factor , breast cancer , neutropenia , incidence (geometry) , risk factor , oncology , chemotherapy regimen , surgery , cancer , physics , optics

Early breast cancer is commonly treated with anthracyclines and taxanes. However, combining these drugs increases the risk of myelotoxicity and may require granulocyte colony-stimulating factor (G-CSF) support. The highest incidence of febrile neutropenia (FN) and largest benefit of G-CSF during the first cycles of chemotherapy lead to questions about the effectiveness of continued use of G-CSF throughout later cycles of chemotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research